Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases
Abstract Background Immune checkpoint inhibitors (ICPIs) are being investigated in clinical trials for patients with glioblastoma. While these therapies hold great promise, management of the patients receiving such treatment can be complicated due to the challenges in recognizing immune-related adve...
Main Authors: | Surabhi Ranjan, Martha Quezado, Nancy Garren, Lisa Boris, Christine Siegel, Osorio Lopes Abath Neto, Brett J. Theeler, Deric M. Park, Edjah Nduom, Kareem A. Zaghloul, Mark R. Gilbert, Jing Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-03-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4131-1 |
Similar Items
-
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Immune checkpoint‑targeted cancer immunotherapies
by: Julian Swatler, et al.
Published: (2016-01-01) -
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
by: Yinghao Zhao, et al.
Published: (2018-05-01) -
INFLUENCE OF ANTIBODIES AGAINST CTLA-4 AND PD-1 UPON QUANTITIES OF THEIR TARGET RECEPTORS
by: I. O. Chikileva, et al.
Published: (2019-01-01) -
Unique cytologic features of thyroiditis caused by immune checkpoint inhibitor therapy for malignant melanoma
by: Trevor E. Angell, et al.
Published: (2018-03-01)